Temat: "breast neoplasms" - OpacWWW

Skocz do pozycji: 1 1.

Tytuł :: Analysis of pathogenic variants in BRCA1 and BRCA2 genes using next-generation sequencing in women with triple negative breast cancer from South India.
Autorzy :: Rajagopal T; Cancer Genomics Laboratory, Department of Biotechnology, School of Chemical and Biotechnology, SASTRA - Deemed University, Thanjavur, 613 401, India.
Seshachalam A; Department of Medical and Paediatric Oncology, Dr.G.V.N Cancer Institute, Singarathope, Trichy, 620 008, India.
Jothi A; Department of Bioinformatics, School of Chemical and Biotechnology, SASTRA - Deemed University, Thanjavur, 613 401, India.
Rathnam KK; Department of Hemato Oncology - Medical Oncology and Bone Marrow Transplantation, Meenakshi Mission Hospital & Research Centre, Madurai, 625 107, India.
Talluri S; Dana Farber Cancer Institute, Boston, MA, 02215, USA.; Veterans Administration Boston Healthcare System, West Roxbury, MA, 02132, USA.
Venkatabalasubranian S; Department of Genetic Engineering, Faculty of Engineering and Technology, SRM Institute of Science and Technology, Kattankulathur Campus, Chennai, Tamil Nadu, 603 203, India.
Dunna NR; Cancer Genomics Laboratory, Department of Biotechnology, School of Chemical and Biotechnology, SASTRA - Deemed University, Thanjavur, 613 401, India. .; Pokaż więcej
Źródło :: Molecular biology reports [Mol Biol Rep] 2022 Apr; Vol. 49 (4), pp. 3025-3032. Date of Electronic Publication: 2022 Jan 12.
Typ publikacji :: Journal Article
MeSH Terms :: BRCA1 Protein*/genetics
BRCA2 Protein*/genetics
Triple Negative Breast Neoplasms*/genetics
Triple Negative Breast Neoplasms*/pathology
Breast Neoplasms/genetics ; Female ; Genes, BRCA2 ; Genetic Predisposition to Disease ; Germ-Line Mutation/genetics ; High-Throughput Nucleotide Sequencing ; Humans ; Ovarian Neoplasms/genetics
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 2 2.

Tytuł :: Accelerating progress to innovation for patients: Trial design and risk stratification.
Autorzy :: Regan MM; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA USA. Electronic address: .; Pokaż więcej
Źródło :: Breast (Edinburgh, Scotland) [Breast] 2022 Mar; Vol. 62 Suppl 1, pp. S80-S83. Date of Electronic Publication: 2021 Nov 20.
Typ publikacji :: Journal Article
MeSH Terms :: Breast Neoplasms*/drug therapy
Clinical Trials as Topic*
Diffusion of Innovation*
Chemotherapy, Adjuvant ; Female ; Humans ; Neoadjuvant Therapy/methods ; Research Design ; Risk Assessment ; Triple Negative Breast Neoplasms/drug therapy
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 3 3.

Tytuł :: Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort.
Autorzy :: Masuda N; Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan. Electronic address: .
Ono M; Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Mukohara T; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Yasojima H; Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan.
Shimoi T; Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Kobayashi K; Department of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Harano K; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Mizutani M; Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan.
Tanioka M; Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Takahashi S; Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Kogawa T; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Suzuki T; Japan and Asia Clinical Development Department, Oncology Business Group, Eisai Co., Ltd., Tokyo, Japan.
Okumura S; Japan and Asia Clinical Development Department, Oncology Business Group, Eisai Co., Ltd., Tokyo, Japan.
Takase T; Clinical Data Science Department, Medicine Development Center, Eisai Co., Ltd., Tokyo, Japan.
Nagai R; Clinical Data Science Department, Medicine Development Center, Eisai Co., Ltd., Tokyo, Japan.
Semba T; Tsukuba Research Department, Oncology Business Group, Eisai Co., Ltd., Ibaraki, Japan.
Zhao ZM; Translational Science, Oncology Business Group, Eisai Inc., Nutley, NJ, USA.
Ren M; Biostats, Oncology Business Group, Eisai Inc., Nutley, NJ, USA.
Yonemori K; Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.; Pokaż więcej
Źródło :: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2022 Jun; Vol. 168, pp. 108-118. Date of Electronic Publication: 2022 Apr 29.
Typ publikacji :: Clinical Trial, Phase I; Journal Article
MeSH Terms :: Breast Neoplasms*/drug therapy
Breast Neoplasms*/pathology
Furans*/adverse effects
Ketones*/adverse effects
Cohort Studies ; Drug Compounding ; Febrile Neutropenia ; Female ; Humans ; Liposomes ; Triple Negative Breast Neoplasms/drug therapy
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 4 4.

Tytuł :: A clinical trial to compare a 3D-printed bolus with a conventional bolus with the aim of reducing cardiopulmonary exposure in postmastectomy patients with volumetric modulated arc therapy.
Autorzy :: Zhang Y; Department of Radiation Oncology, Jiangxi Cancer Hospital of Nanchang University, Nanchang, PR China.
Huang Y; Department of Radiation Oncology, Jiangxi Cancer Hospital of Nanchang University, Nanchang, PR China.
Ding S; Department of Radiation Oncology, Jiangxi Cancer Hospital of Nanchang University, Nanchang, PR China.
Liang J; Department of Radiation Oncology, Jiangxi Cancer Hospital of Nanchang University, Nanchang, PR China.
Kuang J; School of Public Health, Nanchang University, Nanchang, PR China.
Mao Q; Department of Radiation Oncology, Jiangxi Cancer Hospital of Nanchang University, Nanchang, PR China.
Ying W; Department of Radiation Oncology, Jiangxi Cancer Hospital of Nanchang University, Nanchang, PR China.
Shu Y; Department of Radiation Oncology, Jiangxi Cancer Hospital of Nanchang University, Nanchang, PR China.
Li J; Department of Radiation Oncology, Jiangxi Cancer Hospital of Nanchang University, Nanchang, PR China.; Key Laboratory of Personalized Diagnosis and Treatment of Nasopharyngeal Carcinoma Nanchang, Nanchang, PR China.; Medical College of Nanchang University, Nanchang, PR China.
Jiang C; Department of Radiation Oncology, Jiangxi Cancer Hospital of Nanchang University, Nanchang, PR China.; Key Laboratory of Personalized Diagnosis and Treatment of Nasopharyngeal Carcinoma Nanchang, Nanchang, PR China.; Medical College of Nanchang University, Nanchang, PR China.; Pokaż więcej
Źródło :: Cancer medicine [Cancer Med] 2022 Feb; Vol. 11 (4), pp. 1037-1047. Date of Electronic Publication: 2021 Dec 23.
Typ publikacji :: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :: Breast Neoplasms*/radiotherapy
Breast Neoplasms*/surgery
Radiotherapy, Intensity-Modulated*/adverse effects
Radiotherapy, Intensity-Modulated*/methods
Female ; Humans ; Mastectomy ; Organs at Risk ; Printing, Three-Dimensional ; Radiation Pneumonitis/etiology ; Radiotherapy Dosage ; Unilateral Breast Neoplasms/radiotherapy ; Unilateral Breast Neoplasms/surgery
: Czasopismo naukowe

Szczegóły Pełny tekst

Skocz do pozycji: 5 5.

Tytuł :: TRPS1 Expression in Breast Carcinomas: Focusing on Metaplastic Breast Carcinomas.
Autorzy :: Parkinson B; Department of Pathology, Wexner Medical Center at The Ohio State University, Columbus, OH.
Chen W
Shen T
Parwani AV
Li Z; Pokaż więcej
Źródło :: The American journal of surgical pathology [Am J Surg Pathol] 2022 Mar 01; Vol. 46 (3), pp. 415-423.
Typ publikacji :: Journal Article
MeSH Terms :: Biomarkers, Tumor/*metabolism
Breast Neoplasms/*metabolism
Carcinoma/*metabolism
Repressor Proteins/*metabolism
Breast Neoplasms/diagnosis ; Breast Neoplasms/pathology ; Carcinoma/diagnosis ; Carcinoma/pathology ; Case-Control Studies ; Female ; Humans ; Tissue Array Analysis ; Triple Negative Breast Neoplasms/diagnosis ; Triple Negative Breast Neoplasms/metabolism ; Triple Negative Breast Neoplasms/pathology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 6 6.

Tytuł :: Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics.
Autorzy :: Nelson DR; Eli Lilly and Company, Indianapolis, IN, United States of America.
Brown J; Eli Lilly and Company, Bracknell, Surrey, United Kingdom.
Morikawa A; Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States of America.
Method M; Eli Lilly and Company, Indianapolis, IN, United States of America.; Pokaż więcej
Źródło :: PloS one [PLoS One] 2022 Feb 25; Vol. 17 (2), pp. e0264637. Date of Electronic Publication: 2022 Feb 25 (Print Publication: 2022).
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Breast Neoplasms/*mortality
Breast Neoplasms/*pathology
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Breast Neoplasms/drug therapy ; Breast Neoplasms/epidemiology ; Breast Neoplasms, Male/drug therapy ; Breast Neoplasms, Male/epidemiology ; Breast Neoplasms, Male/mortality ; Breast Neoplasms, Male/pathology ; Female ; Humans ; Incidence ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Proportional Hazards Models ; Receptor, ErbB-2/metabolism ; Risk Factors ; Triple Negative Breast Neoplasms/drug therapy ; Triple Negative Breast Neoplasms/mortality ; Triple Negative Breast Neoplasms/pathology ; Young Adult
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 7 7.

Tytuł :: Lumpectomy followed by radiation improves survival in HER2 positive and triple-negative breast cancer with high tumor-infiltrating lymphocytes compared to mastectomy alone.
Autorzy :: Mouabbi JA; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Chand M; Ascension St John Hospital, Detroit, MI, USA.
Asghar IA; Ascension St John Hospital, Detroit, MI, USA.
Sakhi R; Ascension St John Hospital, Detroit, MI, USA.
Ockner D; Ascension St John Hospital, Detroit, MI, USA.
Dul CL; Ascension St John Hospital, Detroit, MI, USA.
Hadid T; Ascension St John Hospital, Detroit, MI, USA.
Aref A; Ascension St John Hospital, Detroit, MI, USA.
Rimawi MF; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Hoyos V; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.; Pokaż więcej
Źródło :: Cancer medicine [Cancer Med] 2021 Jul; Vol. 10 (14), pp. 4790-4795. Date of Electronic Publication: 2021 Jun 03.
Typ publikacji :: Comparative Study; Journal Article
MeSH Terms :: Breast Neoplasms*/chemistry
Breast Neoplasms*/immunology
Breast Neoplasms*/mortality
Breast Neoplasms*/therapy
Lymphocytes, Tumor-Infiltrating*
Mastectomy, Segmental*/mortality
Receptor, ErbB-2*
Adult ; Age Factors ; Aged ; Aged, 80 and over ; Antineoplastic Agents/therapeutic use ; Combined Modality Therapy/methods ; Combined Modality Therapy/mortality ; Disease-Free Survival ; Female ; Humans ; Kaplan-Meier Estimate ; Mastectomy/mortality ; Middle Aged ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Radiotherapy/mortality ; Retrospective Studies ; Time Factors ; Triple Negative Breast Neoplasms/chemistry ; Triple Negative Breast Neoplasms/immunology ; Triple Negative Breast Neoplasms/mortality ; Triple Negative Breast Neoplasms/therapy
: Czasopismo naukowe

Szczegóły Pełny tekst

Skocz do pozycji: 8 8.

Tytuł :: Upregulated WTAP expression appears to both promote breast cancer growth and inhibit lymph node metastasis.
Autorzy :: Wang CQ; Department of Pathology, Affiliated Dongyang Hospital of Wenzhou Medical University, 60 Wu Ning Xi Road, Dongyang, 322100, Zhejiang, People's Republic of China. .
Tang CH; Graduate Institute of Basic Medical Science, China Medical University, Taichung, Taiwan.; Department of Pharmacology, School of Medicine, China Medical University, Taichung, Taiwan.; Department of Biotechnology, College of Health Science, Asia University, Taichung, Taiwan.
Wang Y; Department of Medical Oncology, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, People's Republic of China.
Huang BF; Department of Pathology, Affiliated Dongyang Hospital of Wenzhou Medical University, 60 Wu Ning Xi Road, Dongyang, 322100, Zhejiang, People's Republic of China.
Hu GN; Department of Surgical Oncology, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, People's Republic of China.
Wang Q; Department of Pathology, Affiliated Dongyang Hospital of Wenzhou Medical University, 60 Wu Ning Xi Road, Dongyang, 322100, Zhejiang, People's Republic of China.
Shao JK; Department of Pathology, Affiliated Dongyang Hospital of Wenzhou Medical University, 60 Wu Ning Xi Road, Dongyang, 322100, Zhejiang, People's Republic of China.; Pokaż więcej
Źródło :: Scientific reports [Sci Rep] 2022 Jan 19; Vol. 12 (1), pp. 1023. Date of Electronic Publication: 2022 Jan 19.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Breast Neoplasms/*metabolism
Breast Neoplasms/*pathology
Cell Cycle Proteins/*metabolism
RNA Splicing Factors/*metabolism
Adult ; Aged ; Aged, 80 and over ; Axilla/pathology ; Breast Neoplasms/genetics ; Cell Cycle Proteins/genetics ; China ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Immunohistochemistry ; Lymphatic Metastasis/physiopathology ; Middle Aged ; Neoplasm Staging ; Prognosis ; RNA Splicing Factors/genetics ; Triple Negative Breast Neoplasms/genetics ; Triple Negative Breast Neoplasms/metabolism ; Triple Negative Breast Neoplasms/pathology
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 9 9.

Tytuł :: High chromosome instability identified by low-pass whole-genome sequencing assay is associated with TP53 copy loss and worse prognosis in BRCA1 germline mutation breast cancer.
Autorzy :: Zhu L; Department of Pathology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, 310022, China.; Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, 310022, China.
Pan JN; Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, 310022, China.; Department of Breast Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, 310022, China.; Zhejiang Chinese Medical University, Hangzhou, 310053, China.
Qian Z; Prophet Genomics Inc, San Jose, CA, 95131, USA.; Suzhou Hongyuan Biotech Inc, Biobay, Suzhou, 215123, China.
Ye WW; Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, 310022, China.; Department of Breast Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, 310022, China.
Wang XJ; Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, 310022, China.; Department of Breast Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, 310022, China.
Cao WM; Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, 310022, China. .; Department of Breast Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, 310022, China. .; Pokaż więcej
Źródło :: Breast cancer (Tokyo, Japan) [Breast Cancer] 2022 Jan; Vol. 29 (1), pp. 103-113. Date of Electronic Publication: 2021 Aug 17.
Typ publikacji :: Journal Article
MeSH Terms :: Chromosomal Instability*
Gene Dosage*
Germ-Line Mutation*
BRCA1 Protein/*genetics
Breast Neoplasms/*genetics
Breast Neoplasms/*mortality
Tumor Suppressor Protein p53/*genetics
Adult ; Breast Neoplasms, Male/genetics ; Breast Neoplasms, Male/mortality ; China/epidemiology ; Disease-Free Survival ; Female ; Humans ; Male ; Middle Aged ; Whole Genome Sequencing
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 10 10.

Tytuł :: Cannabinoids in Breast Cancer: Differential Susceptibility According to Subtype.
Autorzy :: Almeida CF; Laboratory of Biochemistry, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, n° 228, 4050-313 Porto, Portugal.; Associate Laboratory i4HB-Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, n° 228, 4050-313 Porto, Portugal.
Teixeira N; Laboratory of Biochemistry, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, n° 228, 4050-313 Porto, Portugal.; Associate Laboratory i4HB-Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, n° 228, 4050-313 Porto, Portugal.
Correia-da-Silva G; Laboratory of Biochemistry, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, n° 228, 4050-313 Porto, Portugal.; Associate Laboratory i4HB-Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, n° 228, 4050-313 Porto, Portugal.
Amaral C; Laboratory of Biochemistry, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, n° 228, 4050-313 Porto, Portugal.; Associate Laboratory i4HB-Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, n° 228, 4050-313 Porto, Portugal.; Pokaż więcej
Źródło :: Molecules (Basel, Switzerland) [Molecules] 2021 Dec 28; Vol. 27 (1). Date of Electronic Publication: 2021 Dec 28.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Breast Neoplasms/*etiology
Breast Neoplasms/*metabolism
Cannabinoids/*pharmacology
Animals ; Breast Neoplasms/drug therapy ; Breast Neoplasms/pathology ; Cannabinoids/chemistry ; Cannabinoids/metabolism ; Cannabinoids/therapeutic use ; Cell Cycle/drug effects ; Cell Cycle/genetics ; Disease Management ; Disease Susceptibility ; Endocannabinoids/metabolism ; Female ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Phytochemicals/metabolism ; Phytochemicals/pharmacology ; Phytochemicals/therapeutic use ; Protein Binding ; Receptors, Cannabinoid/metabolism ; Signal Transduction/drug effects ; Structure-Activity Relationship ; Triple Negative Breast Neoplasms/drug therapy ; Triple Negative Breast Neoplasms/etiology ; Triple Negative Breast Neoplasms/metabolism ; Triple Negative Breast Neoplasms/pathology
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 11 11.

Tytuł :: The A20/TNFAIP3-CDC20-CASP1 Axis Promotes Inflammation-mediated Metastatic Disease in Triple-negative Breast Cancer.
Autorzy :: Song C; Division of Radiology, Mayo Clinic, Rochester, MN, U.S.A.; Mayo High School, Rochester, MN, U.S.A.
Kendi AT; Division of Radiology, Mayo Clinic, Rochester, MN, U.S.A.
Lowe VJ; Division of Radiology, Mayo Clinic, Rochester, MN, U.S.A.; .
Lee S; Division of Radiology, Mayo Clinic, Rochester, MN, U.S.A.; .; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, U.S.A.; Pokaż więcej
Źródło :: Anticancer research [Anticancer Res] 2022 Feb; Vol. 42 (2), pp. 681-695.
Typ publikacji :: Journal Article
MeSH Terms :: Caspase 1/*genetics
Cdc20 Proteins/*genetics
Triple Negative Breast Neoplasms/*genetics
Tumor Necrosis Factor alpha-Induced Protein 3/*genetics
Breast Neoplasms/genetics ; Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; Cell Line, Tumor ; Cytokines/genetics ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Inflammation ; Inflammation Mediators/metabolism ; Neoplasm Metastasis ; Prognosis ; Triple Negative Breast Neoplasms/metabolism ; Triple Negative Breast Neoplasms/pathology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 12 12.

Tytuł :: MAPK4 promotes triple negative breast cancer growth and reduces tumor sensitivity to PI3K blockade.
Autorzy :: Wang W; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
Han D; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
Cai Q; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
Shen T; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
Dong B; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.; Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Lewis MT; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Wang R; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
Meng Y; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.; Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA, USA.
Zhou W; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
Yi P; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
Creighton CJ; Department of Medicine, Baylor College of Medicine, Houston, TX, USA.; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Moore DD; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.; Nutritional Sciences and Toxicology, University of California - Berkeley, Berkeley, CA, USA.
Yang F; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA. .; Pokaż więcej
Źródło :: Nature communications [Nat Commun] 2022 Jan 11; Vol. 13 (1), pp. 245. Date of Electronic Publication: 2022 Jan 11.
Typ publikacji :: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :: Phosphatidylinositol 3-Kinases/*genetics
Phosphatidylinositol 3-Kinases/*metabolism
RNA Helicases/*genetics
RNA Helicases/*metabolism
Triple Negative Breast Neoplasms/*genetics
Animals ; Breast Neoplasms/genetics ; Breast Neoplasms/metabolism ; Cell Line, Tumor ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Mice ; Mice, SCID ; Mitogen-Activated Protein Kinases/metabolism ; PTEN Phosphohydrolase/genetics ; PTEN Phosphohydrolase/metabolism ; Phosphoinositide-3 Kinase Inhibitors/metabolism ; Phosphoinositide-3 Kinase Inhibitors/pharmacology ; Proto-Oncogene Proteins c-akt/metabolism ; Signal Transduction ; TOR Serine-Threonine Kinases/metabolism ; Xenograft Model Antitumor Assays
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 13 13.

Tytuł :: The percentage of residual DCIS in patients diagnosed with primary invasive breast cancer treated with neoadjuvant systemic therapy: A nationwide retrospective study.
Autorzy :: Ploumen RAW; Department of Surgery, Maastricht University Medical Centre+, 6202 AZ, Maastricht, the Netherlands; GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre+, 6200 MD, Maastricht, the Netherlands. Electronic address: .
Keymeulen KBMI; Department of Surgery, Maastricht University Medical Centre+, 6202 AZ, Maastricht, the Netherlands. Electronic address: .
Kooreman LFS; GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre+, 6200 MD, Maastricht, the Netherlands; Department of Pathology, Maastricht University Medical Centre+, 6202 AZ, Maastricht, the Netherlands. Electronic address: .
van Kuijk SMJ; Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre+, 6202 AZ, Maastricht, the Netherlands. Electronic address: .
Siesling S; Department of Health Technology and Services Research, Technical Medical Centre, University of Twente, 7522 NH, Enschede, the Netherlands; Department of Research and Development, Netherlands Comprehensive Cancer Organisation, 3511 DT, Utrecht, the Netherlands. Electronic address: .
Smidt ML; Department of Surgery, Maastricht University Medical Centre+, 6202 AZ, Maastricht, the Netherlands; GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre+, 6200 MD, Maastricht, the Netherlands. Electronic address: .
van Nijnatten TJA; Department of Radiology and Nuclear Medicine, Maastricht University Medical Centre+, 6202 AZ, Maastricht, the Netherlands. Electronic address: .; Pokaż więcej
Źródło :: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology [Eur J Surg Oncol] 2022 Jan; Vol. 48 (1), pp. 60-66. Date of Electronic Publication: 2021 Oct 22.
Typ publikacji :: Journal Article
MeSH Terms :: Neoadjuvant Therapy*
Antineoplastic Agents/*therapeutic use
Breast Neoplasms/*drug therapy
Carcinoma, Ductal, Breast/*drug therapy
Carcinoma, Intraductal, Noninfiltrating/*drug therapy
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Breast Neoplasms/pathology ; Carcinoma, Ductal, Breast/pathology ; Carcinoma, Intraductal, Noninfiltrating/pathology ; Female ; Humans ; Logistic Models ; Mastectomy ; Mastectomy, Segmental ; Middle Aged ; Neoplasm Grading ; Neoplasm Staging ; Neoplasm, Residual ; Receptor, ErbB-2/metabolism ; Receptors, Estrogen/metabolism ; Triple Negative Breast Neoplasms/drug therapy ; Triple Negative Breast Neoplasms/pathology ; Young Adult
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 14 14.

Tytuł :: Role of MRI in predicting response to neo-adjuvant systemic therapy (NAST) in breast cancer.
Autorzy :: Jafferbhoy S; Department of Breast Surgery, University Hospitals of North Midlands, Stoke-on-Trent, United Kingdom.
Gowda S M; Department of Breast Surgery, University Hospitals of North Midlands, Stoke-on-Trent, United Kingdom.
Kabeer KK; Department of Breast Surgery, University Hospitals of North Midlands, Stoke-on-Trent, United Kingdom.
Mohd-Isa Z; Department of Breast Radiology, University Hospitals of North Midlands, Stoke-on-Trent, United Kingdom.
Salehi-Bird S; Department of Breast Radiology, University Hospitals of North Midlands, Stoke-on-Trent, United Kingdom.
Marla S; Department of Breast Surgery, University Hospitals of North Midlands, Stoke-on-Trent, United Kingdom.
Narayanan S; Department of Breast Surgery, University Hospitals of North Midlands, Stoke-on-Trent, United Kingdom.
Soumian S; Department of Breast Surgery, University Hospitals of North Midlands, Stoke-on-Trent, United Kingdom.; Pokaż więcej
Źródło :: Breast disease [Breast Dis] 2022; Vol. 41 (1), pp. 165-173.
Typ publikacji :: Journal Article
MeSH Terms :: Magnetic Resonance Imaging*
Breast Neoplasms/*diagnostic imaging
Breast Neoplasms/*therapy
Neoplasm, Residual/*diagnostic imaging
Adult ; Aged ; Chemotherapy, Adjuvant ; Female ; Humans ; Middle Aged ; Neoadjuvant Therapy ; Receptor, ErbB-2 ; Retrospective Studies ; Triple Negative Breast Neoplasms ; Young Adult
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 15 15.

Tytuł :: Commission on Cancer CP3R Compliance Rates for Treatment of Patients With Triple Negative and HER2+ Breast Cancer: A National Cancer Database Analysis.
Autorzy :: Mohan SC; Department of Surgery, 22494Cedars Sinai Medical Center, Los Angeles, CA, USA.
Tseng J; Department of Surgery, 22494Cedars Sinai Medical Center, Los Angeles, CA, USA.
Srour M; Department of Surgery, 22494Cedars Sinai Medical Center, Los Angeles, CA, USA.
Chung A; Department of Surgery, 22494Cedars Sinai Medical Center, Los Angeles, CA, USA.
Marumoto A; Department of Surgery, 22494Cedars Sinai Medical Center, Los Angeles, CA, USA.
Angarita S; Department of Surgery, 22494Cedars Sinai Medical Center, Los Angeles, CA, USA.
Giuliano AE; Department of Surgery, 22494Cedars Sinai Medical Center, Los Angeles, CA, USA.
Amersi F; Department of Surgery, 22494Cedars Sinai Medical Center, Los Angeles, CA, USA.; Pokaż więcej
Źródło :: The American surgeon [Am Surg] 2021 Dec; Vol. 87 (10), pp. 1539-1544. Date of Electronic Publication: 2021 Oct 21.
Typ publikacji :: Journal Article
MeSH Terms :: Breast Neoplasms/*drug therapy
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers, Tumor ; Breast Neoplasms/pathology ; Chemotherapy, Adjuvant ; Databases, Factual ; Female ; Humans ; Immunotherapy ; Medication Adherence ; Middle Aged ; Neoplasm Staging ; Quality of Health Care ; Receptor, ErbB-2 ; Triple Negative Breast Neoplasms/drug therapy ; Triple Negative Breast Neoplasms/pathology ; United States
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 16 16.

Tytuł :: Profile of patients seen at Pietersburg and Mankweng breast cancer clinics in Limpopo.
Autorzy :: Mavhungu R; Department of General Surgery, Pietersburg and Mankweng hospitals, University of Limpopo, Polokwane, South Africa. .
Bhuiyan M
Ooko F; Pokaż więcej
Źródło :: South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde [S Afr Med J] 2021 Dec 01; Vol. 111 (11b), pp. 1129-1131. Date of Electronic Publication: 2021 Dec 01.
Typ publikacji :: Journal Article
MeSH Terms :: Breast Neoplasms/*epidemiology
Adult ; Aged ; Breast Neoplasms/pathology ; Breast Neoplasms, Male/epidemiology ; Breast Neoplasms, Male/pathology ; Female ; Humans ; Incidence ; Male ; Mammography ; Middle Aged ; Neoplasm Staging ; Prevalence ; Retrospective Studies ; South Africa/epidemiology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 17 17.

Tytuł :: Fat mass and obesity-associated protein (FTO) mediates signal transducer and activator of transcription 3 (STAT3)-drived resistance of breast cancer to doxorubicin.
Autorzy :: Wang Y; Department of Pathology, Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University, the First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China.
Cheng Z; Department of Pathology, Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University, the First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China.
Xu J; Department of Pathology, Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University, the First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China.
Lai M; Department of Pathology, Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University, the First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China.
Liu L; Department of Pathology, Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University, the First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China.
Zuo M; Department of Pathology, Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University, the First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China.
Dang L; Department of Dermatology, Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University, the First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China.; Pokaż więcej
Źródło :: Bioengineered [Bioengineered] 2021 Dec; Vol. 12 (1), pp. 1874-1889.
Typ publikacji :: Journal Article
MeSH Terms :: Alpha-Ketoglutarate-Dependent Dioxygenase FTO/*metabolism
Breast Neoplasms/*pathology
Doxorubicin/*pharmacology
STAT3 Transcription Factor/*metabolism
Alpha-Ketoglutarate-Dependent Dioxygenase FTO/genetics ; Apoptosis/drug effects ; Breast Neoplasms/genetics ; Cell Line, Tumor ; Cell Survival/drug effects ; Drug Resistance, Neoplasm/drug effects ; Drug Resistance, Neoplasm/genetics ; Female ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Promoter Regions, Genetic/genetics ; Protein Binding/drug effects ; STAT3 Transcription Factor/genetics ; Triple Negative Breast Neoplasms/pathology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 18 18.

Tytuł :: Soluble interleukin-2 receptor as a predictive and prognostic marker for patients with familial breast cancer.
Autorzy :: Gonda K; Department of Medicine, Daido Obesity and Metabolism Research Center, Japan.; Department of Medicine, Daido Central Hospital, Japan.; Department of Bioregulation and Pharmacological Medicine, 12775Fukushima Medical University, Japan.; 12775Department of Surgery, Fukushima Medical University, Japan.
Horita S; Department of Bioregulation and Pharmacological Medicine, 12775Fukushima Medical University, Japan.
Maejima Y; Department of Bioregulation and Pharmacological Medicine, 12775Fukushima Medical University, Japan.
Takenoshita S; 12775Department of Surgery, Fukushima Medical University, Japan.
Shimomura K; Department of Bioregulation and Pharmacological Medicine, 12775Fukushima Medical University, Japan.; Pokaż więcej
Źródło :: Science progress [Sci Prog] 2021 Jul-Sep; Vol. 104 (3), pp. 368504211039590.
Typ publikacji :: Journal Article
MeSH Terms :: Interleukin-2*
Triple Negative Breast Neoplasms*
Breast Neoplasms ; C-Reactive Protein ; Humans ; Interleukin-17 ; Ligands ; Prognosis ; Receptors, Interleukin-2 ; Vascular Endothelial Growth Factor A
SCR Disease Name :: Breast Cancer, Familial
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 19 19.

Tytuł :: Presence of human breast cancer xenograft changes the diurnal profile of amino acids in mice.
Autorzy :: Junior RP; Faculdade de Medicina de São José Do Rio Preto, São José do Rio Preto, Brazil. .
Sonehara NM; Faculdade de Medicina de São José Do Rio Preto, São José do Rio Preto, Brazil.
Jardim-Perassi BV; Faculdade de Medicina de São José Do Rio Preto, São José do Rio Preto, Brazil.
Pal A; The Institute of Cancer Research, London, UK.
Asad Y; The Institute of Cancer Research, London, UK.
Almeida Chuffa LG; Universidade Do Estado de São Paulo, São Paulo, Brazil.
Chammas R; Instituto Do Câncer Do Estado de São Paulo, São Paulo, Brazil.
Raynaud FI; The Institute of Cancer Research, London, UK.
Zuccari DAPC; Faculdade de Medicina de São José Do Rio Preto, São José do Rio Preto, Brazil.; Pokaż więcej
Źródło :: Scientific reports [Sci Rep] 2022 Jan 19; Vol. 12 (1), pp. 1008. Date of Electronic Publication: 2022 Jan 19.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Amino Acids/*blood
Circadian Rhythm/*physiology
Mammary Neoplasms, Experimental/*physiopathology
Triple Negative Breast Neoplasms/*physiopathology
Amino Acids/metabolism ; Animals ; Breast Neoplasms/physiopathology ; Cell Line ; Cell Line, Tumor ; Female ; Humans ; Mice ; Neoplasm Transplantation ; Pilot Projects
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 20 20.

Tytuł :: ARSD, a novel ERα downstream target gene, inhibits proliferation and migration of breast cancer cells via activating Hippo/YAP pathway.
Autorzy :: Lin Y; Central laboratory, Cancer Hospital of Shantou University Medical College, 7 Raoping Road, Shantou, 515041, China.
Li C; Faculty of Health science, Hull York Medical School, University of Hull, Hull, UK, HU6 7RX.
Xiong W; Central laboratory, Cancer Hospital of Shantou University Medical College, 7 Raoping Road, Shantou, 515041, China.
Fan L; Central laboratory, Cancer Hospital of Shantou University Medical College, 7 Raoping Road, Shantou, 515041, China.
Pan H; Central laboratory, Cancer Hospital of Shantou University Medical College, 7 Raoping Road, Shantou, 515041, China. .
Li Y; Central laboratory, Cancer Hospital of Shantou University Medical College, 7 Raoping Road, Shantou, 515041, China. .; Pokaż więcej
Źródło :: Cell death & disease [Cell Death Dis] 2021 Nov 02; Vol. 12 (11), pp. 1042. Date of Electronic Publication: 2021 Nov 02.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Hippo Signaling Pathway*/genetics
YAP-Signaling Proteins*/genetics
Arylsulfatases/*genetics
Breast Neoplasms/*genetics
Breast Neoplasms/*pathology
Cell Movement/*genetics
Estrogen Receptor alpha/*metabolism
Arylsulfatases/metabolism ; Base Sequence ; Binding Sites ; Cell Line, Tumor ; Cell Proliferation/genetics ; Chromatin/metabolism ; Chromosomes, Human, X/genetics ; DNA Methylation/genetics ; Disease Progression ; Gene Expression Regulation, Neoplastic ; Histones/metabolism ; Humans ; Middle Aged ; Models, Biological ; Phenotype ; Protein Processing, Post-Translational ; RNA, Long Noncoding/genetics ; RNA, Long Noncoding/metabolism ; Transcription Factors/metabolism ; Triple Negative Breast Neoplasms/genetics ; Triple Negative Breast Neoplasms/pathology ; X Chromosome Inactivation
: Czasopismo naukowe

Szczegóły

Informacja

Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""breast neoplasms"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język